BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 29668904)

  • 21. C57BL/6 Background Attenuates mHTT Toxicity in the Striatum of YAC128 Mice.
    Back MK; Kurzawa J; Ruggieri S; von Engelhardt J
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired Replenishment of Cortico-Striatal Synaptic Glutamate in Huntington's Disease Mouse Model.
    Buren C; Tu G; Raymond LA
    J Huntingtons Dis; 2020; 9(2):149-161. PubMed ID: 32310183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington's disease mouse model.
    Thomson SB; Stam A; Brouwers C; Fodale V; Bresciani A; Vermeulen M; Mostafavi S; Petkau TL; Hill A; Yung A; Russell-Schulz B; Kozlowski P; MacKay A; Ma D; Beg MF; Evers MM; Vallès A; Leavitt BR
    Brain; 2023 Jun; 146(6):2298-2315. PubMed ID: 36508327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Huntingtin Knockin Pig Model Recapitulates Features of Selective Neurodegeneration in Huntington's Disease.
    Yan S; Tu Z; Liu Z; Fan N; Yang H; Yang S; Yang W; Zhao Y; Ouyang Z; Lai C; Yang H; Li L; Liu Q; Shi H; Xu G; Zhao H; Wei H; Pei Z; Li S; Lai L; Li XJ
    Cell; 2018 May; 173(4):989-1002.e13. PubMed ID: 29606351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease.
    Alto LT; Chen X; Ruhn KA; Treviño I; Tansey MG
    PLoS One; 2014; 9(5):e96544. PubMed ID: 24824433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nemo-like kinase reduces mutant huntingtin levels and mitigates Huntington's disease.
    Jiang M; Zhang X; Liu H; LeBron J; Alexandris A; Peng Q; Gu H; Yang F; Li Y; Wang R; Hou Z; Arbez N; Ren Q; Dong JL; Whela E; Wang R; Ratovitski T; Troncoso JC; Mori S; Ross CA; Lim J; Duan W
    Hum Mol Genet; 2020 May; 29(8):1340-1352. PubMed ID: 32242231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease.
    Lerner RP; Trejo Martinez Ldel C; Zhu C; Chesselet MF; Hickey MA
    Brain Res Bull; 2012 Apr; 87(6):571-8. PubMed ID: 22326483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease.
    Shekhar S; Vatsa N; Kumar V; Singh BK; Jamal I; Sharma A; Jana NR
    Hum Mol Genet; 2017 Jan; 26(2):420-429. PubMed ID: 28007908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired development of cortico-striatal synaptic connectivity in a cell culture model of Huntington's disease.
    Buren C; Parsons MP; Smith-Dijak A; Raymond LA
    Neurobiol Dis; 2016 Mar; 87():80-90. PubMed ID: 26711622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
    Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time-Course Analysis of Protein and Lipid Oxidation in the Brains of Yac128 Huntington's Disease Transgenic Mice.
    Brocardo PS; McGinnis E; Christie BR; Gil-Mohapel J
    Rejuvenation Res; 2016 Apr; 19(2):140-8. PubMed ID: 26371883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurochemical correlates of synapse density in a Huntington's disease mouse model.
    Zarate N; Gundry K; Yu D; Casby J; Eberly LE; Öz G; Gomez-Pastor R
    J Neurochem; 2023 Jan; 164(2):226-241. PubMed ID: 36272099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease.
    Silva AC; Ferreira IL; Hayden MR; Ferreiro E; Rego AC
    Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):34-44. PubMed ID: 28939435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
    Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
    J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.
    Gladding CM; Fan J; Zhang LY; Wang L; Xu J; Li EH; Lombroso PJ; Raymond LA
    J Neurochem; 2014 Jul; 130(1):145-59. PubMed ID: 24588402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early TNF-Dependent Regulation of Excitatory and Inhibitory Synapses on Striatal Direct Pathway Medium Spiny Neurons in the YAC128 Mouse Model of Huntington's Disease.
    Chambon J; Komal P; Lewitus GM; Kemp GM; Valade S; Adaïdi H; Al Bistami N; Stellwagen D
    J Neurosci; 2023 Jan; 43(4):672-680. PubMed ID: 36517241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.
    Sepers MD; Smith-Dijak A; LeDue J; Kolodziejczyk K; Mackie K; Raymond LA
    J Neurosci; 2018 Jan; 38(3):544-554. PubMed ID: 29192125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease.
    Franciosi S; Ryu JK; Shim Y; Hill A; Connolly C; Hayden MR; McLarnon JG; Leavitt BR
    Neurobiol Dis; 2012 Jan; 45(1):438-49. PubMed ID: 21946335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene therapy by proteasome activator, PA28γ, improves motor coordination and proteasome function in Huntington's disease YAC128 mice.
    Jeon J; Kim W; Jang J; Isacson O; Seo H
    Neuroscience; 2016 Jun; 324():20-8. PubMed ID: 26944602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.